IC
AIMT

Ikarian Capital’s Aimmune Therapeutics AIMT Stock Holding History

Ikarian Capital’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-326,500
Closed -$11.2M – 272
2020
Q3 		$11.2M Buy
+326,500
New +$6.95M 0.81% 34

Ikarian Capital's AIMT Position: Q1 2020 in Review

Ikarian Capital sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 40,000 shares — an estimated $1.34M sold.

Ikarian Capital first reported a position in AIMT in Q4 2019 and held it in 1 quarter. The position peaked at $1.34M in Q4 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

  • Ikarian Capital reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Ikarian Capital sold 40,000 Aimmune Therapeutics shares in Q1 2020, an estimated $1.34M.
  • Ikarian Capital first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 1 quarter.
  • Ikarian Capital's Aimmune Therapeutics position peaked at $1.34M in Q4 2019.
  • 161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Ikarian Capital's 13F filing for Q1 2020, filed 15 May 2020.